1 |
Sato, N., N. Takahashi, K. Suda, M. Nakamura, M. Yamaki, T. Ninomiya, Y. Kobayashi, H. Takada, K. Shibata, M. Yamamoto, K. Takeda, S. Akira, T. Noguchi, and N. Udagawa. 2004. MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J. Exp. Med. 200: 601-611.
DOI
|
2 |
Sjogren, K., C. Engdahl, P. Henning, U. H. Lerner, V. Tremaroli, M. K. Lagerquist, F. Backhed, and C. Ohlsson. 2012. The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. 27: 1357-1367.
DOI
|
3 |
Terauchi, M., J. Y. Li, B. Bedi, K. H. Baek, H. Tawfeek, S. Galley, L. Gilbert, M. S. Nanes, M. Zayzafoon, R. Guldberg, D. L. Lamar, M. A. Singer, T. F. Lane, H. M. Kronenberg, M. N. Weitzmann, and R. Pacifici. 2009 . T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell. Metab. 10: 229-240.
DOI
|
4 |
Kim, Y. G., C. K. Lee, S. S. Nah, S. H. Mun, B. Yoo, and H. B. Moon. 2007. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 357: 1046-1052.
DOI
|
5 |
Axmann, R., S. Herman, M. Zaiss, S. Franz, K. Polzer, J. Zwerina, M. Herrmann, J. Smolen, and G. Schett. 2008. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67: 1603-1609.
DOI
|
6 |
Zaiss, M. M., B. Frey, A. Hess, J. Zwerina, J. Luther, F. Nimmerjahn, K. Engelke, G. Kollias, T. Hunig, G. Schett, and J. P. David. 2010. Regulatory T cells protect from local and systemic bone destruction in arthritis. J. Immunol. 184: 7238-7246.
DOI
|
7 |
Zaiss, M. M., K. Sarter, A. Hess, K. Engelke, C. Böhm, F. Nimmerjahn, R. Voll, G. Schett, and J. P David. 2010. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis. Rheum. 62: 2328-2338.
DOI
|
8 |
Calvi, L. M, G. B. Adams, K. W. Weibrecht, J. M. Weber, D. P. Olson, M. C. Knight, R. P. Martin, E. Schipani, P. Divieti, F. R. Bringhurst, L. A. Milner, H. M. Kronenberg, and D. T. Scadden. 2003. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-846.
DOI
|
9 |
Arai, F., A. Hirao, M. Ohmura, H. Sato, S. Matsuoka, K. Takubo, K. Ito, G. Y. Koh, and T. Suda. 2004. Tie2/angiopoietin- 1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 118: 149-161.
DOI
|
10 |
Tsay, J., Z. Yang, F. P. Ross, S. Cunningham-Rundles, H. Lin, R. Coleman, P. Mayer-Kuckuk, S. B. Doty, R. W. Grady, P. J. Giardina, A. L. Boskey, and M. G. Vogiatzi. 2010. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood 116: 2582-2589.
DOI
|
11 |
Grainger, R. G. and J. W. Laws. 1957. Paget's disease; active or quiescent? Br. J. Radiol. 30: 120-124.
DOI
|
12 |
Sato, K., A. Suematsu, K. Okamoto, A. Yamaguchi, Y. Morishita, Y. Kadono, S. Tanaka, T. Kodama, S. Akira, Y. Iwakura, D. J. Cua, and H. Takayanagi. 2006. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203: 2673- 2682.
DOI
|
13 |
Ali, T., D. Lam, M. S. Bronze, and M. B. Humphrey. 2009. Osteoporosis in inflammatory bowel disease. Am. J. Med. 122: 599-604.
DOI
|
14 |
Papadaki, M. E., S. A. Lietman, M. A. Levine, B. R. Olsen, L. B. Kaban, and E. J. Reichenberger. 2012. Cherubism: best clinical practice. Orphanet. J. Rare. Dis. 7 Suppl 1: S6.
DOI
|
15 |
Karmakar, S., J. Kay, and E. M. Gravallese. 2010. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum. Dis. Clin. North. Am. 36: 385-404.
DOI
|
16 |
Seriolo, B., S. Paolino, A. Sulli, V. Ferretti, and M. Cutolo. 2006. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1069: 420-427.
DOI
|
17 |
Kotake, S., N. Udagawa, N. Takahashi, K. Matsuzaki, K. Itoh, S. Ishiyama, S. Saito, K. Inoue, N. Kamatani, M. T. Gillespie, T. J. Martin, and T. Suda. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103: 1345-1352.
DOI
|
18 |
Takayanagi, H., K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, K. Nakamura, and T. Taniguchi. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408: 600-605.
DOI
|
19 |
Gao, Y., F. Grassi, M. R. Ryan, M. Terauchi, K. Page, X. Yang, M. N. Weitzmann, and R. Pacifici. 2007. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen- driven T cell activation. J. Clin. Invest. 117: 122-132.
DOI
|
20 |
Liu, Y., L. Wang, T. Kikuiri, K. Akiyama, C. Chen, X. Xu, R. Yang, W. Chen, S. Wang, and S. Shi. 2011. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γand TNF-. Nat. Med. 17: 1594- 1601.
DOI
|
21 |
Gao, Y., X. Wu, M. Terauchi, J. Y. Li, F. Grassi, S. Galley, X. Yang, M. N. Weitzmann, and R. Pacifici. 2008. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell. Metab. 8: 132-145.
DOI
|